Skip to content
Screener

CapEx at other companies

Insulet logo
InsuletPODD
$32.5M+74.7%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$4.05M-34.7%
Medtronic logo
MedtronicMDT
$488M+6.3%
Embecta Corp. logo
Embecta Corp.EMBC
$1.1M+175%
AdaptHealth logo
AdaptHealthAHCO
$121.21M+26.8%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$4.17M+167%

Other financials

Income statement

See full
Revenue$32.0M+37.8%
Gross profit$18.9M+51.2%
Operating income-$25.6M-28.7%
Net income-$23.4M-38.7%
EPS (diluted)-$0.53-35.9%

Balance sheet

See full
Cash & equivalents$44.3M+26.4%
Total debt$6.5M-2.6%
Total equity$256.4M-15.0%
Total assets$292.4M-11.4%

Cash flow

See full
Operating cash flow-$14.6M-7.6%
Free cash flow-$15.7M-1.9%

Valuation

See full
Market cap$715.34M+15.1%
Enterprise value$677.53M+14.2%
P/S-2.0×

Profitability

See full
Gross margin58.3%+4.4pp
Operating margin-69.8%-8.0pp
Net margin-61.3%-15.8pp
FCF margin-51.6%-13.4pp

Returns & leverage

See full
Return on equity-26.2%
Debt / equity0.0×
Current ratio8.9×-5.8×

Where this comes from

Reported directly by Beta Bionics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323777
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Purchases of short-term investments(190,768)
Purchases of long-term investments(44,812)(31,069)
Proceeds from maturities and redemptions of short-term investments96,00051,000
Purchases of property and equipment(2,416)(2,112)
Net cash provided by (used in) investing activities48,772(172,949)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discounts, commissions and issuance costs195,430
Proceeds from the issuance of common stock from private placement, net of issuance costs15,591

Item 1. Financial Statements.

FAQ

What is Beta Bionics's capex?
Beta Bionics (BBNX) reported capex of $1.04M in Q2 2026.
How has Beta Bionics's capex changed year-over-year?
Beta Bionics's capex decreased by 41.6% year-over-year, from $1.78M to $1.04M.
What is the long-term trend for Beta Bionics's capex?
Over 2 years (2023 to 2025), Beta Bionics's capex has grown at a 263.0% compound annual growth rate (CAGR), from $402K to $5.3M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

Ask your AI about Beta Bionics's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude